In conclusion, these findings suggest that IGF2BP3 has the potential to be a biomarker for identifying more aggressive subtypes of breast cancer, particularly TNBC, and it has good clinical value in diagnosing TNBC. This evidence concerns the gene IGF2BP3 and breast cancer.